In vitro Interactions of Chicken Programmed Cell Death 1 (PD-1) and PD-1 Ligand-1 (PD-L1)

被引:6
|
作者
Reddy, Vishwanatha R. A. P. [1 ]
Mwangi, William [1 ]
Sadigh, Yashar [1 ]
Nair, Venugopal [1 ]
机构
[1] Pirbright Inst, Viral Oncogenesis Grp, Pirbright, England
基金
英国生物技术与生命科学研究理事会;
关键词
chPD-1; chPD-L1; monoclonal antibodies; cancer; pathways; T-CELLS; ANTIBODY; EXHAUSTION; EXPRESSION; PATHWAY; BINDING; SAFETY;
D O I
10.3389/fcimb.2019.00436
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
In the present study, we determined the in vitro characteristics and binding interactions of chicken PD-1 (chPD-1) and PD-L1 (chPD-L1) and developed a panel of specific monoclonal antibodies against the two proteins. ChPD-1 and chPD-L1 sequence identities and similarities were lower compared with those of humans and other mammalian species. Furthermore, in phylogenetic analysis, chPD-1 and chPD-L1 were grouped separately from the mammalian PD-1 and PD-L1 sequences. As in other species, chPD-1 and chPD-L1 sequences showed signal peptide, extracellular domain, a transmembrane domain and intracellular domain. Based on the three dimensional (3D) structural homology, chPD-1, and chPD-L1 were similar to 3D structures of mammalian PD-1 and PD-L1. Further, Ig V domain of chPD-1 and the Ig V and Ig C domains of chPD-L1 were highly conserved with the mammalian counterparts. In vitro binding interaction studies using Superparamagnetic Dynabeads (R) confirmed that recombinant soluble chPD-1/PD-L1 fusion proteins and surface chPD-1/PD-L1 proteins interacted with each other on COS cells. Two monoclonal antibodies specific against chPD-1 and five antibodies against chPD-L1 were developed and their specific binding characteristics confirmed by immunofluorescence staining and Western blotting.
引用
收藏
页数:9
相关论文
共 50 条
  • [21] Prognostic Impact of Programmed Cell Death-1 (PD-1) and PD-Ligand 1 (PD-L1) Expression in Thymic Cancer
    Funaki, S.
    Shintani, Y.
    Ose, N.
    Kawamura, T.
    Kanzaki, R.
    Minami, M.
    Okumura, M.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S2064 - S2065
  • [22] Programmed Death-1 (PD-1) and Programmed Death-Ligand 1 (PD-L1) Expression in Aggressive Pediatric Lymphomas
    Coffey, Amy M.
    Curry, Jonathan L.
    Marcogliese, Andrea N.
    Tetzlaff, Michael T.
    Kamdar, Kala
    Elghetany, Mohamed T.
    Curry, Choladda V.
    [J]. LABORATORY INVESTIGATION, 2017, 97 : 344A - 344A
  • [23] Programmed Death-1 (PD-1) and Programmed Death-Ligand 1 (PD-L1) Expression in Aggressive Pediatric Lymphomas
    Coffey, Amy M.
    Curry, Jonathan L.
    Marcogliese, Andrea N.
    Tetzlaff, Michael T.
    Kamdar, Kala
    Elghetany, Mohamed T.
    Curry, Choladda V.
    [J]. MODERN PATHOLOGY, 2017, 30 : 344A - 344A
  • [24] Prognostic Significance of Programmed Cell Death 1 (PD-1) or PD-1 Ligand 1 (PD-L1) Expression in Epithelial-Originated Cancer A Meta-Analysis
    Zhang, Yaxiong
    Kang, Shiyang
    Shen, Jianfei
    He, Jiaxi
    Jiang, Long
    Wang, Wei
    Guo, Zhihua
    Peng, Guilin
    Chen, Gang
    He, Jianxing
    Liang, Wenhua
    [J]. MEDICINE, 2015, 94 (06) : e515
  • [25] Clinicopathological value of programmed cell death 1 (PD-1) and programmed cell death ligand 1 (PD-L1) expression in synovium of patients with rheumatoid arthritis
    Matsuda, Kotaro
    Miyoshi, Hiroaki
    Hiraoka, Koji
    Hamada, Tetsuya
    Yoshida, Shiro
    Ishibashi, Yukinao
    Haraguchi, Toshiaki
    Shiba, Naoto
    Ohshima, Koichi
    [J]. CLINICAL AND EXPERIMENTAL MEDICINE, 2018, 18 (04) : 487 - 494
  • [26] Clinicopathological value of programmed cell death 1 (PD-1) and programmed cell death ligand 1 (PD-L1) expression in synovium of patients with rheumatoid arthritis
    Kotaro Matsuda
    Hiroaki Miyoshi
    Koji Hiraoka
    Tetsuya Hamada
    Shiro Yoshida
    Yukinao Ishibashi
    Toshiaki Haraguchi
    Naoto Shiba
    Koichi Ohshima
    [J]. Clinical and Experimental Medicine, 2018, 18 : 487 - 494
  • [27] Programmed Cell Death 1 (PD-1) and Programmed Cell Death Ligand 1 (PD-L1) Expression Patterns in Ewing and Ewing-Like Sarcoma
    Tamura, A.
    Yoshida, M.
    Yamamoto, N.
    Nakamura, S.
    Fujiwara, T.
    Tahara, T.
    Saito, A.
    Kozaki, A.
    Kishimoto, K.
    Ishida, T.
    Hasegawa, D.
    Kosaka, Y.
    [J]. PEDIATRIC BLOOD & CANCER, 2018, 65 : S336 - S336
  • [28] PD-1/PD-L1 inhibitors
    Sunshine, Joel
    Taube, Janis M.
    [J]. CURRENT OPINION IN PHARMACOLOGY, 2015, 23 : 32 - 38
  • [29] Programmed death-1 (PD-1) and programmed death-ligand 1 (PD-L1) expressions in type 2 endometrial cancer
    Umran Kucukgoz Gulec
    Emine Kilic Bagir
    Semra Paydas
    Ahmet Baris Guzel
    Derya Gumurdulu
    Mehmet Ali Vardar
    [J]. Archives of Gynecology and Obstetrics, 2019, 300 : 377 - 382
  • [30] Prognostic significance of programmed death-1 (PD-1) and programmed death-ligand 1 (PD-L1) expression in uterine carcinosarcoma
    Gulec, Umran Kucukgoz
    Bagir, Emine Kilic
    Paydas, Semra
    Guzel, Ahmet Baris
    Gumurdulu, Derya
    Vardar, Mehmet Ali
    [J]. EUROPEAN JOURNAL OF OBSTETRICS & GYNECOLOGY AND REPRODUCTIVE BIOLOGY, 2020, 244 : 51 - 55